Purpose: To analyse the frequencies of histological findings, predictive factors for the presence of undifferentiated tumor and variables influencing the survival of patients with nonseminomatous germ cell tumors who underwent secondary resection of residual masses after cisplatin-based combination chemotherapy.
Introduction
Metastatic testicular cancer has become a model for a curable neoplasm. With the introduction of cisplatinbased combination chemotherapy, approximately 50% to 80% of patients presenting with disseminated nonseminomatous germ cell tumors will achieve long-term survival [1] . Surgical resection of residual tumor masses is an essential part of the treatment [2] . In most patients, residual masses are located in the retroperitoneal space and the resection is performed as a retroperitoneal lymph node dissection or lumpectomy. Additionally, residual pulmonary metastases will be considered for postchemotherapy resection. These surgical procedures may be associated with long-term morbidity in some patients, even if improved techniques are used [3, 4] .
Following chemotherapy, the resected residual masses may histologically contain either necrosis, differentiated teratoma or even undifferentiated tumor. For patients with undifferentiated tumor, the secondary resection may prolong survival depending on the biological aggressiveness of the disease, the completeness of surgery and the effectiveness of further additive treatment [5] . The resection of differentiated teratoma may prevent local tumor growth and late disease recurrence with possible malignant transformation [6] [7] [8] . In case of necrosis, patients will have no improvement of their prognosis by the operation beyond the diagnosis of a pathologic CR. Identification of those patients prior to the surgical intervention would be of benefit in order to prevent surgery-related complications [9] [10] [11] [12] [13] . Only the excision of all residual tumors provides a definitive histological diagnosis [15, 16] . The current analysis investigates the outcome of patients with metastatic non-seminomatous germ cell tumors who underwent resections of Table 1 Characteristics of patients undergoing postchemotherapy resection of residual masses from metastatic testicular cancer after cisplatin-based combination chemotherapy between 1978-1995 at diag- residual masses at a single or at multiple localisations after cisplatin-based first-line or second-line chemotherapy for metastatic disease.
Patients and methods
Between 1978 and 1995, 134 patients underwent secondary resection after cisplatin-based combination chemotherapy from metastatic nonseminomatous germ cell tumors at Hannover University Medical School. One hundred nine (81%) of them were operated after first-line chemotherapy and 25 (19%) after salvage chemotherapy for relapsed disease after previous CR.
The median age at diagnosis was 25 years for the patients receiving first-line chemotherapy (range 15-44) and 28 years (range 20-47) for patients receiving second-line chemotherapy. One hundred twentysix patients had tumors of testicular origin, six had retroperitoneal extragonadal germ cell tumors, whereas no patients with primary mediastinal tumors were included. In two cases no primary tumor were found, but a considerable elevation of serum J3-HCG and AFP indicated the presence of a NSGCT. Histology was classified according to the British Tumor Panel [17] . The staging investigations prior to and after completion of chemotherapy consisted of physical examination, laboratory testing including serum tumor markers (5-HCG, AFP and LDH, chest X-ray and abdominal/thoracic CT scans and of all other initially involved sites. Patients were classified according to the Indiana University Classification [18] . Characteristics including histology of the primary tumor, number of metastatic sites, extent of disease and tumor markers for both patients undergoing surgery after firstand second-line chemotherapy are summarized in 
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summarized in Table 2 [19] [20] [21] [22] . None of the included patients was treated with radiation therapy. Complete remission (CR) was defined as a complete disappearance of all clinical, radiological and biochemical evidence of disease. A partial response with marker normalisation (PRm-) was defined as any decrease in tumor size and normalisation of the tumor markers. PR without marker normalisation (PRm+) was defined as a radiological response > 50% in size but no complete normalisation of p^HCG and/or AFP at the end of chemotherapy. Progressive disease was defined as either residual lesions increasing in size or occurrence of new lesions and/or elevation of tumor markers at repeated controls. Size criteria for performing a retroperitoneal intervention was a residual mass > 1 cm and at thoracic sites > 0.5-1 cm in diameter at CTscan. To restrict the extent of the surgical intervention, retroperitoneal operations were routinely performed as a lumpectomy. In case of undifferentiated tumor, all lymph nodes even without enlargement were resected in this localisation (formal RPLND). Immunohistochemical tumor marker stains were used in some patients if undifferentiated tumor was suspected. One hundred thirty-eight surgical interventions were performed in 109 patients after first-line chemotherapy, 27 patients were operated at two localisations and two patients at three sites. The type of surgical intervention is outlined in Table 2 . Surgery was carried out within three months after the end of chemotherapy. Multiple surgical interventions were performed within a 3-6-week interval, except for five patients with one-stage operations. The histological findings of postchemotherapy surgery were classified as necrosis, differentiated teratoma or undifferentiated tumor. In case of undifferentiated tumor, patients were scheduled to receive two additional cycles of cisplatin/ifosfamide-based chemotherapy, mainly the VIP-regimen [21] . Complete resection (R0) was defined as excision of all residual tumors with clear surgical margins. Patients were classifed as incompletely resected by evidence of a makroscopically visuable residual mass (R2) or if the surgical margins were not clear in histological examination (Rl).
During the first two years, follow-up examinations were performed three-monthly. The interval was thereafter prolonged to six months in the third year and to annually from the fourth year on. For all living patients, the current status as of August 1995 was gained. The KaplanMeier method [23] was used to determine the overall and relapse-free survival distributions assessed from the date of the last surgical intervention. The overall survival calculation used death due to any reason as the endpoint. In the first-line group the relapse-free period ended with surgery-related death in one case and treatment/disease unrelated death in another patient (travel accident). Apart from the results of the histological examination at postchemotherapy resection, the extent of disease at primary diagnosis, localisation of the tumor residuals prior to surgery, pre-and postchemotherapy tumor marker status, time interval to relapse and the completeness of resection were examined for their impact on survival in univariate analysis. Comparisons were made using the log-rank test. Cox regression was applied to model the simultaneous effects of several variables. Significance for entry was calculated from a likelihood ratio (LR) statistic [24] . A forward stepwise selection method was used with P < 0 05 as an entry criterion. The calculated odds ratio (OR) may be interpreted as relative risk. Multivariate logistic regression analyis was performed to estimate the probability of undifferentiated tumor to be found at postchemotherapy resection based on the combination of preoperative variables The multivariate analysis included all factors with P < 0 05 identified in preceeding univariate analysis [25] . All statistical analyses were performed using SPSS for Windows 6.0 software (Microsoft Corp., Redmond, WA, USA).
Results

/. Resections after first-line chemotherapy (n pts -109)
Histological findings
At the time of surgical intervention 82 patients (75%) had partial remissions with marker normalisation, 11 patients were PRm+ (10%) and for 12 patients (11%) progressive disease without marker normalisation was documentated. Four patients had a partial remission and unknown marker status. Patients with progressive disease and increasing tumor markers after chemotherapy included in this analysis underwent 'desperation surgery' for lack of a effective salvage chemotherapy in the years before 1988.
Necrosis, differentiated teratoma and undifferentiated tumor were found in 46%, 22% and 32% of all patients. In the subgroup of 82 patients with PRm-the distribution was 52% necrosis, 27% differentiated teratoma and 21% undifferentiated tumor. Among 11 patients with PRm+, three of seven patients showing a decrease of tumor markers but failed to completely normalize prior to operation (marker slope) had undifferentiated carcinoma, whereas in all four remaining patients with rising tumor markers shortly after chemotherapy undifferentiated tumor was found. Of 12 patients classified as progressive disease, eight (67%) had undifferentiated tumor; differentiated teratoma was found in two (17%) and necrosis in the other two patients (17%). A clear correlation between response status after chemotherapy and the histological results was found (P = 0.001).
The estimated five-year progression-free survival rates for all 109 patients according to histological findings at postchemotherapy resection were similar with 78% for necrosis, 67% for differentiated teratoma and 66% for undifferentiated tumor. In 21% of retroperitoneal resections mature teratoma was found (n -92 operations) compared to 33% at thoractomy (n -36 operations). There was a tendency for undifferentiated carcinoma to be found more often in the retroperitoneal area (33%) compared to the lungs (17%) (P = 0.06).
Resection grade and histological findings
In 82 patients (75%) complete resection of residual tumors was achieved, while in 24 cases resections were incomplete (n.e. = 3 pts). In patients with multiple resections the worst result per patient was taken into account. No difference was found in obtaining a complete surgical excision with respect to different tumor localisations, particularly comparing the retroperitoneal space and the lungs (76% versus 71%). Patients with 'advanced disease' at initial diagnosis more frequently received only incomplete resections (P = 0.04). Incomplete resection was statistically associated with the persistence of undifferentiated tumor since 22 of 24 patients with incomplete resections had undifferentiated tumors (P -0.002). Remarkably, these patients had only a slightly decreased two-year survival rate of 83% following surgery plus additive chemotherapy. The two-year survival rate for patients with resection of necrosis or mature teratoma were 93% and 90%, respectively.
In 13 of 25 patients (52%) who relapsed, the recurrence occurred at the initial resection area, two of them (8%) with evidence of new metastases at other sites. In 12 patients (48%), the relapse was located only outside of the initially resected area. Eight of the 13 patients (62%) who relapsed after postchemotherapy surgery at the previously operated localisation have had a complete resection.
Predictive factors for histological findings
Neither elevated tumor markers at initial diagnosis, extent of disease, number and localisation of the metastases nor the histology of the primary tumor at diagnosis -especially presence of teratomatous elements -did influence the histological findings at secondary resection. In multivariate logistic regression analysis incompleteness of surgery was associated with a high likelihood for the persistence of undifferentiated tumor (odds ratio = 4.6) ( Table 3) . Decreased but not normalized values for (3-HCG and AFP possessed a higher relative risk for undifferentiated tumor (OR = 1.39). Patients with progressive disease or rising tumor markers (n -16) were excluded from this analysis because, as mentioned above, remission status after chemotherapy was highly predictive for the finding of undifferentiated tumor.
Survival
At the end of the study period, 92 of 109 patients (84%) were alive, 78 (72%) of them without evidence of disease and 14 patients (12%) with active disease. The median observation time was 35 months (range 1-169). The estimated five-year overall and relapse-free survival rates were 80% and 66%, respectively. Fifteen patients had died of metastatic testicular cancer during the observation period. Surgery-related mortality was 1%. Early relapse within three months after secondary resection, persisting AFP, elevated LDH at diagnosis or initial massive mediastinal lymph nodes involvement at primary diagnosis were identified as negative prognostic factors for survival (Table 4) . Patients with residual masses at several localisations undergoing multiple resections had an estimated five-year survival of 68% in contrast to 82% for patients operated only at one site (« = 82) (/> = 0.14).
Patients with resections at multiple sites
Necrotic tissue was found in 18 (67%), differentiated teratoma in four (15%) and undifferentiated tumor in five patients (19%) at the first site, and in 18 (67%), one (4%) and eight patients (30%) at the second surgically resected site, respectively. Two patients underwent a third surgical intervention yielding undifferentiated tumor and necrosis. In total, 10 patients (37%) had undifferentiated tumor in at least one resected specimen. A correlation between the completeness of resection and the histological finding was detectable, since only incomplete resections were possible in 9 of 12 patients revealing undifferentiated tumor (P -0.006). Eight of 27 patients (30%) showed dissimilar histological findings at the different sites. Among 18 patients who underwent both excision of retroperitoneal and thoracic residuals, a less favorable finding was found in two patients at the retroperitoneal site and in one at thoracotomy. Considering all surgical interventions, necrosis was more frequently found at thoracotomy (n = 15/21) compared to retroperitoneal surgery (n = 17/27) (P = 0.05). Of two patients who underwent bilateral thoracotomy, one showed necrosis at both sites and the other had dissimilar findings with differentiated teratoma and undifferentiated tumor. All resections of hepatic lesions revealed necrotic tissue (n = 4). The histology was identical at three retroperitoneal resections and but once undifferentiated carcinoma was found.
//. Resections after second-line chemotherapy (n pts = 25)
Twenty-five patients underwent postchemotherapy resections after second-line cisplatin-based combination chemotherapy. Only 40% had reached a normalisation of elevated P-HCG and/or AFP after second-line chemotherapy prior to the operation. In 14 patients, complete resection of residual masses was possible, among them all patients with marker normalisation. Twenty patients (80%) had undifferentiated tumors in their resected specimens. The distribution of histological findings in the remaining five patients was necrosis in four (16%) and differentiated teratoma in one (4%). Comparing the survival data of these patients to those operated after first-line chemotherapy, the prognosis was significantly worse with a calculated five-year survival of 44% (P < 0.0001).
In case of undifferentiated tumor in the specimen, further chemotherapy seemed to have no influence on survival since 13 patients with post-surgery chemotherapy and seven without had a comparable five-year survival (38% versus 43%). Complete resection of undifferentiated tumor resulted in a five-year survival of 50% versus 30% in cases with incomplete resections (n.s.). Of nine patients with completely resected undifferentiated carcinoma, additionally receiving postopera- Abbreviations: -= not available; nee = necrosis, td = differentiated teratoma; ut = undifferentiated tumor; ctx = chemotherapy; DDP = cisplatin, Ifo = ifosfamide, Eto = etoposide, Vbl = vinblastin. " Estimated five-years survival [23] .
tive chemotherapy, four remained disease-free at two years.
Discussion
Postchemotherapy resection is an established part of the treatment in metastatic non-seminomatous germ cell tumors if residual tumor masses are radiologically detectable. About 15% to 20% of those abnormalities will histologically contain undifferentiated tumor, 45% to 50% necrotic tissue and 30% to 40% mature teratoma, as recently confirmed in a report including nearly a thousand patients from different institutions [25] . In our series either undifferentiated tumor or differentiated teratoma were found in 54% of patients. In case of either necrosis or differentiated teratoma, no further treatment is necessary. It would be useful to identify patients harbouring necrosis in residual masses prior to the operation in order to prevent surgery-related morbidity and mortality. On the other hand, surgical resection of differentiated teratoma is useful in order to prevent recurrent teratoma or a subsequent malignant transformation [26] [27] [28] . Undifferentiated tumor in the resected specimens may indicate a poor prognosis and additional chemotherapy is often used in these patients. Recently, Steyerberg et al. performed a meta-analysis based on 556 patients with non-seminomatous germ cell tumors operated after first-line chemotherapy in order to develop a statistical model for the prediction of the histology of residual masses [29] . Independent predictive factors for necrosis were the absence of teratomatous elements in the primary tumor, prechemotherapy normal AFP/p-HCG values, elevated LDH, small pre-or postchemotherapy masses or a shrinkage of the masses < 70% during chemotherapy. To distinguish undifferentiated tumor from teratoma, a higher prechemotherapy LDH level, a larger postchemotherapy mass and a smaller relative shrinkage of the mass were of value, based on 299 patients in the second analysis. These models were useful to predict necrosis, but were less valuable for the distinction of undifferentiated tumor from mature teratoma.
The proposed model may be helpful for the decision to operate patients immediately or to follow their residual tumors closely, dependent on the calculated risk score. However, there is a high incidence of dissimilar histological findings in resected masses from different localisations in the same individuum, as demonstrated in patients requiring more than one resection. Different histological results were reported ranging between 25%-47% in five studies and in our series 8 of 27 patients (30%) had dissimilar histological findings [30] [31] [32] [33] [34] . A possible explanation might be that the systemic chemotherapy may have different effects on each metastatic subpopulation, depending on pharmacological characteristics of the applied drugs, the size of the metastases, blood delivery of the affected organ and local growth conditions. Since the pretreatment characteristics included in the calculation of Steyerberg et al. were certainly identical within one single patient, the observed variation of histological findings among different sites demonstrates that the prediction remains difficult. However, relative shrinkage of the masses was not evaluated in our patients and in all other series.
Survival dala of a total of 776 patients with metastatic non-seminomatous germ cell tumors from eight larger series undergoing surgical resections after first-line cisplatin-based chemotherapy is summarised in Table 5 .
The data reported, demonstrate that between 72%-89% of patients will remain disease-free at three years after surgery. The finding of necrosis and/or differentiated teratoma in the resected specimens resulted in a 78%-92% and 67%-95% long-term survival rate, respectively [3, 6, 12, [35] [36] [37] [38] .
In 1981, Einhorn et al. reported that patients with undifferentiated tumor at postchemotherapy resection have a poor prognosis with a long-term survival in only 2 of 22 patients. Four of the 22 patients had received cisplatin-based additive chemotherapy after surgery and both long-term survivors were in that group [9] . In the meantime, other investigations have confirmed that the use of cisplatin-based additive chemotherapy may improve the outcome of patients after the resection of vital carcinoma with 56% to 70% of patients reported to be disease-free at three years [6, 11, 37, 39] . Three investigations demonstrated clear differences for disease-free survival between patients receiving postoperative chemotherapy or no further treatment. In Tait's investigation among 12 patients treated postoperatively, six remained disease-free, in contrast to one of four patients without additive chemotherapy [11] . Fox reported an overall disease-free survival of 56% in 43 patients (follow-up: 36 months), while the 27 patients with postoperative cisplatin-based chemotherapy had a disease-free survival of 74% [6] . Donohue et al. from the same institution found 19 of 27 patients (70%) being continuously disease-free with postoperative chemotherapy in contrast to none of seven patients without [39] . In our series, a five-year disease-free survival of 66% was calculated with additive chemotherapy being routinely used in case of undifferentiated carcinoma in resected specimen. Surprisingly, no statistically significant difference in survival between patients with incompletely and completely resected undifferentiated tumors was found in our patients in contrast to several reports [12, 13, 37, 38, 40] . This might be partly explained by the use of extended postoperative chemotherapy for patients (3-4 cycles) with incomplete resections. In the series of Gerl et al., only one recurrence was observed at a site of an incompletely resected mass, although incomplete resection predicted a worse outcome [37] . We found 13 patients who relapsed locally at their previous resection site and only five of them had had non-complete surgical resections. The extent of initial tumor burden correlates inversely with the frequency of complete resections [13, 37] and, as expected, the duration of the relapse-free interval was considered to be important for outcome. A short time to relapse (<3 months) was associated with a worse subsequent survival as shown before by Donohue and other investigators [25, 37, 38, 41] .
The overall survival of the patients being resected after first-line chemotherapy with respect to the number of surgical interventions and of patients after secondline chemotherapy is shown in Figure 1 . There was no statistical significant survival difference detectable between patients with only single or with multiple resections after first-line chemotherapy.
Patients after second-line chemotherapy had the worst prognosis reflecting the lower effectiveness of chemo- therapy. Undifferentiated tumor was found in 80% these patients [6, 39, 42] . Although the use of additive chemotherapy seems to increase the chance for long-term cure in case of surgical resection of vital carcinoma after firstline chemotherapy, the effect of additive chemotherapy was not demonstrable in the salvage chemotherapy setting. This was in accordance to Donohue et al. who have noted the same findings in a large series of 93 patients undergoing resections after second-line chemotherapy [39] . Among 40 patients in his series who had 'desperation surgery' defined as localised resectable markerpositive disease, 25% remained continuously diseasefree. In our series, 3 of 15 patients (20%) achieved longterm survival with surgery used in a comparable situation. With a long-term survival of approximately 40% in the whole group of our patients with salvage chemotherapy, the surgical removal of residual tumors appears to be a useful approach. However, due to the small number of patients available for the analysis after secondline chemotherapy, no solid conclusions can be drawn. Thus, we were not able to detect a significant survival difference between incomplete and complete resections as reported by Donohue et al. However, in contrast to our series, these authors had defined incomplete resection as either unclear tumor margins at operation or the occurrence of a rapid local relapse despite clear surgical margins. The latter event occurred in 24 of 36 patients, retrospectively classified as incompletely resected, thus selecting a subset of patients with a worse prognosis on the basis of the clinical course.
The management of patients with multiple residual masses at different localisations after chemotherapy is controversly discussed. Most investigators advise the excision of all tumor residuals [5, 11, 32, 33, 40] . A recently published investigation has shown that one-stage resection of neck, chest and abdominal residuals may be a safe approach in selected patients at an experienced center [31] . No differences in the complication rate was found in our patients if surgery was carried out either as a sequential (« = 22) or as a one-stage procedure (n = 5). Dissimilar histological results at different anatomical localisations were detected in 30% of patients in accordance to other investigations and a tendency towards more unfavorable histologies in the retroperitoneal compared to the pulmonary residuals was found (P = 0.05) [30] [31] [32] [33] [34] 43] .
Recently, positron emission tomography with marked 2-fluoro-2-deoxyglucose molecules (FDG) is under investigation in patients with metastatic testicular cancer. PET-FDG imaging may be useful for the detection of residual carcinoma. However, the distinction between necrosis and differentiated teratoma may still remain difficult since both tissues have a relatively low metabolic activity [44] . It may be speculated for patients with multiple residual masses that the combination of a negative result at PET-examination at all sites and necrotic tissue found at the retroperitoneal resection may identify those patients who can be spared from resections at other sites. Another important advance for PET-FDG examination could be the identification of patients with undifferentiated tumor prior to the operation. Despite marker normalisation, we found undifferentiated tumor in 17 of 82 patients (21%) after first-line chemotherapy.
In summary, secondary resection of tumor residuals after first-and second-line chemotherapy is still an essential part of the treatment of metastatic testicular cancer. More accurate prognostic models and the use of PET imaging might further help to identify residual undifferentiated tumors and may guide decisions about the operative procedure particularly in patients with technically feasible operations.
